---
title: "Ker-ching!"
description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member."
url: "https://cbrneworld.com/news/subscribers/ker-ching"
date: "2026-07-30T21:11:11+00:00"
language: "en-GB"
---

#  Ker-ching!

 Written by S Johnson on 08 May 2010.

Emergent Biosolutions announced a $51 million contract from BARDA for the development of a new anthrax vaccine utilising their protective antigen rPA. This antigen stimulates a protective immune-response that neutralises the anthrax toxins – which has long been an element of concern.

Meanwhile Cleveland BioLabs snagged a $45 million contract from CBMS for their CBLB502 radiation countermeasure. $14.8 million of this is for advanced development of the countermeasure while the remained is for purchase, after FDA approval, of the necessary dosage for US Forces.

 [Radiation](https://cbrneworld.com/component/tags/tag/radiation), [Contract](https://cbrneworld.com/component/tags/tag/contract)

## Schema

```json
{ "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "News", "item": "https://cbrneworld.com/news" }, { "@type": "ListItem", "position": 2, "name": "Subscribers", "item": "https://cbrneworld.com/news/subscribers" }, { "@type": "ListItem", "position": 3, "name": "Ker-ching!", "item": "https://cbrneworld.com/news/subscribers/ker-ching" } ] }
```

```json
{ "@context": "https://schema.org", "@type": "NewsArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://cbrneworld.com/news/subscribers/ker-ching" }, "headline": "Ker-ching!", "description": "Emergent Biosolutions announced a $51 million contract from BARDA for the development of a new anthrax vaccine utilising their protective antigen rPA. This antigen stimulates a protective immune-response that neutralises the anthrax toxins – which has long been an element of concern.Meanwhile Cleveland BioLabs snagged a $45 million contract from CBMS for their CBLB502 radiation countermeasure. $14.8 million of this is for advanced development of the countermeasure while the remained is for purchase, after FDA approval, of the necessary dosage for US Forces.", "image": { "@type": "ImageObject", "url": "https://cbrneworld.com/" }, "publisher": { "@type": "Organization", "name": "CBRNe World Magazine", "logo": { "@type": "ImageObject", "url": "https://cbrneworld.com/images/default/Asset%201.png" } }, "author": { "@type": "Person", "name": "Ben Bray", "url": "https://cbrneworld.com/news/subscribers/ker-ching" }, "datePublished": "2010-05-08T21:16:48+01:00", "dateCreated": "2010-05-08T21:16:48+01:00", "dateModified": "2018-12-14T15:55:28+00:00" }
```